November 23, 2022

To,
Dy. General Manager
Department of Corporate Services,
Ltd., BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Re: *Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

Dear Sir,

Sub: Update on the US FDA inspection of Glenmark's Goa manufacturing facility

We refer to our letter dated 27th August 2022 informing you about the Official Action Indicated (OAI) status of the Company's Goa (India) manufacturing facility by US FDA following the inspection conducted in May 2022. We wish to inform you that the US FDA has now issued a warning letter to the Goa (India) facility.

The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The Company is committed to work along with the US FDA to implement all the necessary corrective actions required to address the concerns at the earliest. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.

This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2022.11.23 22:11:24 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com